Literature DB >> 27886695

Pathogenesis and Management of Sarcopenia.

Robinder J S Dhillon1, Sarfaraz Hasni2.   

Abstract

Sarcopenia represents a loss of muscle strength and mass in older individuals. Sarcopenia in the elderly has now become a major focus of research and public policy debate due to its impact on morbidity, mortality, and health care expenditure. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice. This is, in part, due to a lack of available diagnostic testing and uniform diagnostic criteria. The management of sarcopenia is primarily focused on physical therapy for muscle strengthening and gait training. There are no pharmacologic agents for the treatment of sarcopenia. Published by Elsevier Inc.

Entities:  

Keywords:  Aging; Fall risk; Frailty; Muscle atrophy; Muscle strength; Sarcopenia; Senescence; Skeletal muscle mass loss

Mesh:

Year:  2017        PMID: 27886695      PMCID: PMC5127276          DOI: 10.1016/j.cger.2016.08.002

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  55 in total

1.  Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).

Authors:  G Abellan van Kan; J M Cderbaum; M Cesari; P Dahinden; R G Fariello; R A Fielding; B H Goodpaster; S Hettwer; M Isaac; D Laurent; J E Morley; M Pahor; D Rooks; R Roubenoff; S B Rutkove; A Shaheen; S Vamvakas; J W Vrijbloed; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-12       Impact factor: 4.075

Review 2.  Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness.

Authors:  James G Ryall; Jonathan D Schertzer; Gordon S Lynch
Journal:  Biogerontology       Date:  2008-02-26       Impact factor: 4.277

3.  The numbers of limb motor neurons in the human lumbosacral cord throughout life.

Authors:  B E Tomlinson; D Irving
Journal:  J Neurol Sci       Date:  1977-11       Impact factor: 3.181

4.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

5.  The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study.

Authors:  Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-10       Impact factor: 6.053

Review 6.  Inflammatory burden and amino acid metabolism in cancer cachexia.

Authors:  William J Durham; Edgar Lichar Dillon; Melinda Sheffield-Moore
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2009-01       Impact factor: 4.294

7.  Anthropometric assessment of 10-y changes in body composition in the elderly.

Authors:  Virginia A Hughes; Ronenn Roubenoff; Michael Wood; Walter R Frontera; William J Evans; Maria A Fiatarone Singh
Journal:  Am J Clin Nutr       Date:  2004-08       Impact factor: 7.045

Review 8.  Phase II drugs that are currently in development for the treatment of cachexia.

Authors:  Anne-Marie C Dingemans; Judith de Vos-Geelen; Ramon Langen; Annemie M W Schols
Journal:  Expert Opin Investig Drugs       Date:  2014-07-24       Impact factor: 6.206

9.  Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.

Authors:  Matteo Cesari; Roger A Fielding; Marco Pahor; Bret Goodpaster; Marc Hellerstein; Gabor A van Kan; Stefan D Anker; Seward Rutkove; J Willem Vrijbloed; Maria Isaac; Yves Rolland; Christine M'rini; Mylène Aubertin-Leheudre; Jesse M Cedarbaum; Mauro Zamboni; Cornell C Sieber; Didier Laurent; William J Evans; Ronenn Roubenoff; John E Morley; Bruno Vellas
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-08-03       Impact factor: 12.910

10.  The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats.

Authors:  Mareike S Pötsch; Anika Tschirner; Sandra Palus; Stephan von Haehling; Wolfram Doehner; John Beadle; Andrew J S Coats; Stefan D Anker; Jochen Springer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-11-22       Impact factor: 12.910

View more
  80 in total

Review 1.  Hippo pathway effectors YAP and TAZ and their association with skeletal muscle ageing.

Authors:  Iwan Setiawan; Ardo Sanjaya; Ronny Lesmana; Paul M Yen; Hanna Goenawan
Journal:  J Physiol Biochem       Date:  2021-01-26       Impact factor: 4.158

2.  Profiling age-related muscle weakness and wasting: neuromuscular junction transmission as a driver of age-related physical decline.

Authors:  Carlos J Padilla; Markus E Harrigan; Hallie Harris; Jan M Schwab; Seward B Rutkove; Mark M Rich; Brian C Clark; W David Arnold
Journal:  Geroscience       Date:  2021-04-24       Impact factor: 7.713

Review 3.  Application of a Social-Ecological Model to Study the Factors Associated With Sarcopenia.

Authors:  Junya Shimamoto; Jun Watanabe; Kazuhiko Kotani
Journal:  Cureus       Date:  2022-05-23

Review 4.  The Key Role of Nutritional Elements on Sport Rehabilitation and the Effects of Nutrients Intake.

Authors:  Sousana K Papadopoulou; Maria Mantzorou; Foivi Kondyli-Sarika; Ioanna Alexandropoulou; Jannis Papathanasiou; Gavriela Voulgaridou; Pantelis T Nikolaidis
Journal:  Sports (Basel)       Date:  2022-05-26

5.  Lysyl oxidase-like 2 inhibitor rescues D-galactose-induced skeletal muscle fibrosis.

Authors:  Yongxin Wu; Yaoxuan Wu; Yunfei Yang; Jing Yu; Jianghao Wu; Zhiyin Liao; Ai Guo; Yue Sun; Yuxing Zhao; Jinliang Chen; Qian Xiao
Journal:  Aging Cell       Date:  2022-06-17       Impact factor: 11.005

6.  Handgrip strength as a valid practical tool to screen early-onset sarcopenia in acute care wards: a first evaluation.

Authors:  Marie Blanquet; Guillaume Ducher; Anaïs Sauvage; Sylvain Dadet; Vincent Guiyedi; Nicolas Farigon; Candy Guiguet-Auclair; Pauline Berland; Jérôme Bohatier; Yves Boirie; Laurent Gerbaud
Journal:  Eur J Clin Nutr       Date:  2021-04-13       Impact factor: 4.016

7.  Comparison of EWGSOP-1and EWGSOP-2 diagnostic criteria on prevalence of and risk factors for sarcopenia among Iranian older people: the Bushehr Elderly Health (BEH) program.

Authors:  Gita Shafiee; Ramin Heshmat; Afshin Ostovar; Fatemeh Khatami; Noushin Fahimfar; Seyed Masoud Arzaghi; Safoora Gharibzadeh; Sara Hanaei; Iraj Nabipour; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2020-05-29

Review 8.  Irisin-Associated Neuroprotective and Rehabilitative Strategies for Stroke.

Authors:  Melissa Ann Huberman; Nathan D d'Adesky; Qismat Bahar Niazi; Miguel A Perez-Pinzon; Helen M Bramlett; Ami P Raval
Journal:  Neuromolecular Med       Date:  2021-07-03       Impact factor: 3.843

9.  Effects of Functional Training on Sarcopenia in Elderly Women in the Presence or Absence of ACE Inhibitors.

Authors:  Marianna Mile; László Balogh; Gábor Papp; József Márton Pucsok; Krisztina Szabó; Lilla Barna; Zoltán Csiki; István Lekli
Journal:  Int J Environ Res Public Health       Date:  2021-06-19       Impact factor: 3.390

10.  Association between protoporphyrin IX and sarcopenia: a cross sectional study.

Authors:  Chia-Chun Kao; Zhe-Yu Yang; Wei-Liang Chen
Journal:  BMC Geriatr       Date:  2021-06-26       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.